Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds

Karki, Subhas S.; Thota, Sreekanth; Darj, Satyanarayana Y.; Balzarini, Jan; Clercq, Erik De

doi:10.1016/j.bmc.2007.08.014

Cited by 58 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ruthenium should also offer reduced toxicity, since its chemistry similar to that of iron, making it able to bind biomolecules such as transferrin [3]. Thus, there are some ruthenium complexes with remarkably low general toxicity, in preclinical or clinical trials, which show efficacy against several kinds of cancer and metastases [4][5][6][7]. Recently our research group has published some results showing that ruthenium/diphosphine complexes are promising as potential anticancer drugs; and here we present some ruthenium/diphosphine/amino acid complexes that also displayed good cytotoxic activity against the tumor cells MDA-MB-231, DU-145 (human), and Ehrlich (mouse), but lower activity against healthy cells (L-929, mouse) [7].…”

Section: Introductionmentioning

confidence: 99%

Structural features and cytotoxic activities of [Ru(AA-H)(dppb)(bipy)]PF6 complexes

et al. 2014

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Structural features and cytotoxic activities of [Ru(AA-H)(dppb)(bipy)]PF6 complexes

et al. 2014

View full text Add to dashboard Cite

“…We have reported that Ru(II) compounds bearing thiosemicarbazides, 8-hydroxyquinolines, and 4-substituted thiopicolinanalides have in vivo anticancer and in vitro antibacterial activity [33][34][35] . Recently, we have reported that Ru(II) compounds bearing isatin thiosemicarbazones and chloro-fluoro-phenyl imino methyl phenol have in vivo anticancer and in vitro cytotoxic activity 36 . In this work, we describe the synthesis and characterization of some ruthenium complexes, their in vitro cytotoxic activity against human cancer cell lines Molt 4/C 8 and CEM and murine tumor cell line L1210, and their in vivo anticancer activity against transplantable murine tumor cell line EAC (Ehrlisch's ascites carcinoma).…”

Section: Introductionmentioning

confidence: 99%

Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes

Thota¹,

Karki²,

Jayaveera³

et al. 2010

Journal of Enzyme Inhibition and Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

“…(18)) and subsequently chelated it to ruthenium-1,10-phenathroline and 2,2'-bipyridine derivatives [138]. The compounds were tested in vitro against leukemic human (MOLT 4/C8 and CEM) and murine (L1210) cell lines.…”

Section: Metal Complexesmentioning

confidence: 99%

Recent Highlights in the Development of Isatin-Based Anticancer Agents

Vine¹,

Matesic²,

Locke³

et al. 2013

Advances in Anticancer Agents in Medicinal Chemistry

View full text Add to dashboard Cite

Isatin (1H-indole-2,3-dione) and its derivatives are responsible for a broad spectrum of biological activities. Among these the cytotoxic and antineoplastic properties have been the most widely reported. The synthetic versatility of the isatin, due to its privileged scaffold, has led to the generation of a large number of structurally diverse derivatives which include analogues derived from either mono-, di-, and trisubstitution of the aryl ring A, and/or those obtained by derivatisation of the isatin nitrogen and C2/C3 carbonyl moieties. These compounds inhibit cancer cell proliferation and tumour growth via interaction with a variety of intracellular targets such as DNA, telomerase, tubulin, P-glycoprotein, protein kinases and phosphatases. Herein we review recent highlights in the development of isatin-based compounds as anticancer agents with a particular focus on the cytotoxicity and structure activity relationships. Abstract:Isatin (1H-indole-2,3-dione) and its derivatives are responsible for a broad spectrum of biological activities. Among these the cytotoxic and antineoplastic properties have been the most widely reported. The synthetic versatility of the isatin, due to its privileged scaffold, has led to the generation of a large number of structurally diverse derivatives which include analogues derived from either mono-, di-, and tri-substitution of the aryl ring A, and/or those obtained by derivatisation of the isatin nitrogen and C2/C3 carbonyl moieties. These compounds inhibit cancer cell proliferation and tumour growth via interaction with a variety of intracellular targets such as DNA, telomerase, tubulin, Pglycoprotein, protein kinases and phosphatases. Herein we review recent highlights in the development of isatin-based compounds as anticancer agents with a particular focus on the cytotoxicity and structure activity relationships.

show abstract

Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds

Cited by 58 publications

References 36 publications

Structural features and cytotoxic activities of [Ru(AA-H)(dppb)(bipy)]PF6 complexes

Structural features and cytotoxic activities of [Ru(AA-H)(dppb)(bipy)]PF6 complexes

Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes

Recent Highlights in the Development of Isatin-Based Anticancer Agents

Contact Info

Product

Resources

About